Alpha 2.0
Login Register
» Articles » PMID: 19196307

Primary Cutaneous Melanoma: a Complication of Infliximab Treatment?

Overview
Journal Clin Exp Dermatol
Publisher Oxford University Press
Specialty Dermatology
Date 2009 Feb 7
PMID 19196307
Citations 6
Authors
I Khan
L Rahman
D B McKenna
Affiliations
Soon will be listed here.
Citing Articles

Malignant transformation of neurocutaneous melanosis (NCM) following immunosuppression.

Schaff L, Marghoob A, Rosenblum M, Meyer R, Khakoo Y Pediatr Dermatol. 2019; 36(4):497-500.

PMID: 30868657 PMC: 6620153. DOI: 10.1111/pde.13804.

Dermal Lesions and Skin Cancer in Patients with Inflammatory Bowel Disease Receiving Immunosuppressive Therapy.

Giagkou E, Saridi M, Albani E, Gaitanis G, Katsanos A, Bechlioulis A Asian Pac J Cancer Prev. 2018; 19(10):2845-2851.

PMID: 30362311 PMC: 6291021. DOI: 10.22034/APJCP.2018.19.10.2845.

Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn's disease: a case report and review of the hypothetical association between TNF-α blockers and cancer.

Kouklakis G, Efremidou E, Pitiakoudis M, Liratzopoulos N, Polychronidis A Drug Des Devel Ther. 2013; 7:195-9.

PMID: 23569358 PMC: 3615922. DOI: 10.2147/DDDT.S41889.

Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence?.

Finet A, Amini-Adle M, Balme B, Colson F, Thomas L Clin Rheumatol. 2012; 32(2):277-80.

PMID: 23138884 DOI: 10.1007/s10067-012-2114-1.

Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.

Long M, Martin C, Pipkin C, Herfarth H, Sandler R, Kappelman M Gastroenterology. 2012; 143(2):390-399.e1.

PMID: 22584081 PMC: 4065572. DOI: 10.1053/j.gastro.2012.05.004.